NCT06629363View on ClinicalTrials.gov

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

Not yet recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 1, 2036

Study Completion Date

April 1, 2036

Conditions
Malignant Hypertension
Interventions
OTHER

biobank

"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"

All Listed Sponsors
lead

Centre Hospitalier de PAU

OTHER

NCT06629363 - Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank | Biotech Hunter | Biotech Hunter